Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Iradimed (IRMD) EBITDA (2016 - 2026)

Iradimed has reported EBITDA over the past 14 years, most recently at $7.2 million for Q1 2026.

  • Quarterly EBITDA rose 33.23% to $7.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $7.8 million through Mar 2026, down 65.73% year-over-year, with the annual reading at $6.0 million for FY2025, 72.88% down from the prior year.
  • EBITDA was $7.2 million for Q1 2026 at Iradimed, up from -$13.1 million in the prior quarter.
  • Over five years, EBITDA peaked at $7.2 million in Q1 2026 and troughed at -$13.1 million in Q4 2025.
  • The 5-year median for EBITDA is $5.2 million (2023), against an average of $4.2 million.
  • Year-over-year, EBITDA skyrocketed 125.93% in 2022 and then plummeted 325.79% in 2025.
  • A 5-year view of EBITDA shows it stood at $4.3 million in 2022, then grew by 21.3% to $5.2 million in 2023, then increased by 12.42% to $5.8 million in 2024, then tumbled by 325.79% to -$13.1 million in 2025, then surged by 155.26% to $7.2 million in 2026.
  • Per Business Quant, the three most recent readings for IRMD's EBITDA are $7.2 million (Q1 2026), -$13.1 million (Q4 2025), and $6.8 million (Q3 2025).